Novel Pullulan Bioconjugate for Selective Breast Cancer Bone Metastases Treatment

Bioconjugate Chemistry

Volumn 26, Issue 3, 2015, Pages 489-501

  Bonzi, Gwénaëlle ^a   Salmaso, Stefano ^a   Scomparin, Anna ^b   Eldar Boock, Anat ^b   Satchi Fainaro, Ronit ^b   Caliceti, Paolo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BONE; CELLS; DISEASES; HYDROXYAPATITE; PATHOLOGY;

ALENDRONATE; BIOCONJUGATES; BISPHOSPHONATES; BONE METASTASIS; BREAST CANCER; PACLITAXEL; POLYMERIC BACKBONE; PULLULANS; SELF-IMMOLATIVE; TETRA PEPTIDE;

BIOMOLECULES;

ALENDRONIC ACID; CATHEPSIN K; HYDROXYAPATITE; NANOCONJUGATE; PACLITAXEL; PULLULAN; TETRAPEPTIDE; GLUCAN;

ANIMAL CELL; ANIMAL CELL CULTURE; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CELL; CHEMICAL STRUCTURE; CRITICAL MICELLE CONCENTRATION; DRUG CONJUGATION; DRUG RELEASE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; MIGRATION INHIBITION; NONHUMAN; OSTEOSARCOMA CELL; SYNTHESIS; UMBILICAL VEIN ENDOTHELIAL CELL; WOUND HEALING; ANIMAL; BONE NEOPLASMS; BREAST NEOPLASMS; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; FEMALE; MOUSE; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

MURINAE;

ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GLUCANS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; TREATMENT OUTCOME;

EID: 84924953776     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc500614b     Document Type: Article

References (51)

1. Colleoni, M., O'Neill, A., Goldhirsch, A., Gelber, R. D., Bonetti, M., Thurlimann, B., Price, K. N., Castiglione-Gertsch, M., Coates, A. S., and Lindtner, J. 2000, Identifying breast cancer patients at high risk for bone metastases J. Clin. Oncol. 18, 3925-35
2. Weilbaecher, K. N., Guise, T. A., and McCauley, L. K. (2011) Cancer to bone: a fatal attraction Nat. Rev. Cancer 11, 411-425
3. Piccoli, A. (2014) Breast cancer bone metastases: an orthopedic emergency J. Orthopedic Traumatology 15, 143-144
4. Uludag, H. (2002) Bisphosphonates as a foundation of drug delivery to bone Curr. Pharm. Des. 8, 1929-44
5. Rosen, L. S., Gordon, D., Tchekmedyian, N. S., Yanagihara, R., Hirsh, V., Krzakowski, M., Pawlicki, M., de Souza, P., Zheng, M., and Urbanowitz, G. 2004, Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial Cancer 100, 2613-2621
6. Morris, G. J. and Mitchell, E. P. (2007) Bisphosphonate therapy for women with breast cancer and at high risk for osteoporosis J. Natl. Med. Assoc. 99, 35-45
7. Hillner, B. E., Ingle, J. N., Chlebowski, R. T., Gralow, J., Yee, G. C., Janjan, N. A., Cauley, J. A., Blumenstein, B. A., Albain, K. S., and Lipton, A. 2003, American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer J. Clin. Oncol. 21, 4042-4057
8. Russell, R. G. G. (2011) Bisphosphonates: The first 40 years Bone 49, 2-19
9. Jagdev, S. P., Coleman, R. E., Shipman, C. M., Rostami-H, A., and Croucher, P. I. (2001) The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel Br. J. Cancer 84, 1126-1134
10. Rose, W. C. (1992) Taxol: a review of its preclinical in vivo antitumor activity Anti-Cancer Drugs 3, 311-322
11. Kiss, L., Walter, F. R., Bocsik, A., Veszelka, S., Ózsvári, B., Puskás, L. G., Szabó-révész, P., and Deli, M. A. (2013) Kinetic analysis of the toxicity of pharmaceutical excipients cremophor EL and RH40 on endothelial and epithelial cells J. Pharm. Sci. 102, 1173-1181
12. Ma, P. and Mumper, R. J. (2013) Paclitaxel nano-delivery systems: a comprehensive review J. Nanomed. Nanotechnol. 4, 1000164
13. Nehate, C., Jain, S., Saneja, A., Khare, V., Alam, N., Dubey, R., and Gupta, P. N. (2014) Paclitaxel formulations: challenges and novel delivery options Curr. Drug Delivery 11, 666-86
14. Eldar-Boock, A., Miller, K., Sanchis, J., Lupu, R., Vicent, M. J., and Satchi-Fainaro, R. (2011) Integrin-assisted drug delivery of nano-scaled polymer therapeutics bearing paclitaxel Biomaterials 32, 3862-3874
15. Singer, J. W. (2005) Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane J. Controlled Release 109, 120-6
16. Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., and Saleh, M. N. 2013, Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine New Engl. J. Med. 369, 1691-703
17. Uludag, H., Kousinioris, N., Gao, T., and Kantoci, D. (2000) Bisphosphonate conjugation to proteins as a means to impart bone affinity Biotechnol. Prog. 16, 258-267
18. Pabst, A. M., Ziebart, T., Ackermann, M., Konerding, M. A., and Walter, C. (1996) Bisphosphonates' antiangiogenic potency in the development of bisphosphonate-associated osteonecrosis of the jaws: influence on microvessel sprouting in an in vivo 3D Matrigel assay Biol. Pharm. Bull. 19, 1026-1031
19. Miller, K., Erez, R., Segal, E., Shabat, D., and Satchi-Fainaro, R. (2009) Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate Angew. Chem., Int. Ed. 48, 2949-54
20. Miller, K., Eldar-Boock, A., Polyak, D., Segal, E., Benayoun, L., Shaked, Y., and Satchi-Fainaro, R. (2011) Antiangiogenic antitumor activity of HPMA copolymer-paclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model Mol. Pharmaceutics 8, 1052-62
21. Saravanakumar, G., Park, J. H., Kim, K., and Kwon, I. C. (2011) Polysaccharide-Based Drug Conjugates for Tumor Targeting, in Drug Delivery in Oncology, pp 701-746, Wiley-VCH Verlag GmbH & Co. KGaA.
22. Rose, A. A. N. and Siegel, P. M. (2009) Emerging therapeutic targets in breast cancer bone metastasis Future Oncol. 6, 55-74
23. Leathers, T. D. (2003) Biotechnological production and applications of pullulan Appl. Microbiol. Biotechnol. 62, 468-73
24. Lee, S. J., Hong, G. Y., Jeong, Y. I., Kang, M. S., Oh, J. S., Song, C. E., and Lee, H. C. (2012) Paclitaxel-incorporated nanoparticles of hydrophobized polysaccharide and their antitumor activity Int. J. Pharm. 433, 121-8
25. Paranjpe, P. V., Chen, Y., Kholodovych, V., Welsh, W., Stein, S., and Sinko, P. J. (2004) Tumor-targeted bioconjugate based delivery of camptothecin: design, synthesis and in vitro evaluation J. Controlled Release 100, 275-292
26. Haratake, M., Matsumoto, S., Ono, M., and Nakayama, M. (2008) Nanoparticulate glutathione peroxidase mimics based on selenocystine-pullulan conjugates Bioconjugate Chem. 19, 1831-1839
27. Scomparin, A., Salmaso, S., Bersani, S., Satchi-Fainaro, R., and Caliceti, P. (2011) Novel folated and non-folated pullulan bioconjugates for anticancer drug delivery Eur. J. Pharm. Sci. 42, 547-58
28. Everts, V., and Beertsen, W. (2005) External lysosomes: the osteoclast and its unique capacities to degrade mineralised tissues, in Lysosomes (Saftig, P., Ed.) pp 144-155, Chapter 12, Springer Science, New York.
29. Bruneel, D. and Schacht, E. (1993) Chemical modification of pullulan: 1. Periodate oxidation Polymer 34, 2628-2632
30. Goldspiel, B. R. (1997) Clinical overview of the taxanes Pharmacotherapy 17, 110S-125S
31. Jasmin, C., Capanna, R., Coia, L., Coleman, R., and Saillant, G. (2005) Textbook of Bone Metastases, Wiley.
32. Lijana, R. C. and Williams, M. C. (1987) Reduction of hemolytic blood damage with dextran. AIChE 33.
33. Cerda-Cristerna, B. I., Flores, H., Pozos-Guillén, A., Pérez, E., Sevrin, C., and Grandfils, C. (2011) Hemocompatibility assessment of poly(2-dimethylamino ethylmethacrylate) (PDMAEMA)-based polymers J. Controlled Release 153, 269-277
34. Miller, K., Clementi, C., Polyak, D., Eldar-Boock, A., Benayoun, L., Barshack, I., Shaked, Y., Pasut, G., and Satchi-Fainaro, R. (2013) Poly(ethylene glycol)-paclitaxel-alendronate self-assembled micelles for the targeted treatment of breast cancer bone metastases Biomaterials 34, 3795-3806
35. de Groot, F. M. H., Loos, W. J., Koekkoek, R., van Berkom, L. W. A., Busscher, G. F., Seelen, A. E., Albrecht, C., de Bruijn, P., and Scheeren, H. W. (2001) Elongated multiple electronic cascade and cyclization spacer systems in activatible anticancer prodrugs for enhanced drug release J. Org. Chem. 66, 8815-8830
36. Carl, P. L., Chakravarty, P. K., and Katzenellenbogen, J. A. (1981) A novel connector linkage applicable in prodrug design J. Med. Chem. 24, 479-480
37. LoPachin, R. M. and Gavin, T. (2014) Molecular mechanisms of aldehyde toxicity: a chemical perspective Chem. Res. Toxicol. 27, 1081-1091
38. Abdel-Magid, A. F., Carson, K. G., Harris, B. D., Maryanoff, C. A., and Shah, R. D. (1996) Reductive amination of aldehydes and ketones with sodium triacetoxyborohydride. Studies on direct and indirect reductive amination procedures J. Org. Chem. 61, 3849-3862
39. Johnson, M. R. and Rickborn, B. (1970) Sodium borohydride reduction of conjugated aldehydes and ketones J. Org. Chem. 35, 1041-1045
40. Gimenez, V., James, C., Arminan, A., Schweins, R., Paul, A., and Vicent, M. J. (2012) Demonstrating the importance of polymer-conjugate conformation in solution on its therapeutic output: Diethylstilbestrol (DES)-polyacetals as prostate cancer treatment J. Controlled Release 159, 290-301
41. Bae, Y. H. and Park, K. (2011) Targeted drug delivery to tumors: Myths, reality and possibility J. Controlled Release 153, 198-205
42. Kong, G., Braun, R. D., and Dewhirst, M. W. (2000) Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size Cancer Res. 60, 4440-5
43. Amiji, M. M. (2006) Nanotechnology for Cancer Therapy; Taylor & Francis.
44. Vader, P., Fens, M. H., Sachini, N., van Oirschot, B. A., Andringa, G., Egberts, A. C., Gaillard, C. A., Rasmussen, J. T., van Wijk, R., and van Solinge, W. W. 2013, Taxol((R))-induced phosphatidylserine exposure and microvesicle formation in red blood cells is mediated by its vehicle Cremophor((R)) EL Nanomedicine (London) 8, 1127-35
45. Markovsky, E., Baabur-Cohen, H., Eldar-Boock, A., Omer, L., Tiram, G., Ferber, S., Ofek, P., Polyak, D., Scomparin, A., and Satchi-Fainaro, R. (2012) Administration, distribution, metabolism and elimination of polymer therapeutics J. Controlled Release 161, 446-460
46. Duncan, R. (2003) The dawning era of polymer therapeutics Nat. Rev. Drug Discovery 2, 347-360
47. Merrifield, R. B. (1963) Solid phase peptide synthesis. I. The synthesis of a tetrapeptide J. Am. Chem. Soc. 85, 2149
48. Snyder, S. L. and Sobocinski, P. Z. (1975) An improved 2,4,6-trinitrobenzenesulfonic acid method for the determination of amines Anal. Biochem. 64, 284-288
49. Kuljanin, J., Janković, I., Nedeljković, J., Prstojević, D., and Marinković, V. (2002) Spectrophotometric determination of alendronate in pharmaceutical formulations via complex formation with Fe(III) ions J. Pharm. Biomed. Anal. 28, 1215-1220
50. Skoog, B. (1979) Determination of polyethylene glycols 4000 and 6000 in plasma protein preparations Vox Sanguinis 37, 345-349
51. Goddard, E. D., Turro, N. J., Kuo, P. L., and Ananthapadmanabhan, K. P. (1985) Fluorescence probes for critical micelle concentration determination Langmuir 1, 352-355